Table 2.

Variables predicting occurrence of clinical disease reactivation in pregnancy and postpartum in the generation cohort.

VIPRiMS			HR	95% CI	P-value	Risk score points
Relapse in year before conception		≥1 relapse in year before conception	3.1	1.2–4.3	<0.001	2
		<1 relapse in year before conception	Ref.			0
EDSS before conception	≥3	1.9	1.1–3.1	0.023	1
		<3	Ref.			0
DMT type before conception		Highly-effective DMT (H-DMT)	4.3	2.5–7.1	<0.001	3
		Moderately-effective DMT (M-DMT)	1.8	0.8–3.5	0.097	0
		No DMT	Ref.			0
Duration of DMT wash-out phase	H-DMT	>12 weeks	3.2	2.1–4.3	<0.001	2
		4–12 weeks	2.3	1.4–4.1	<0.001	1
		<4 weeks	Ref.			0
	M-DMT	>12 weeks	2.0	1.2–3.7	0.004	1
		≤ 12 weeks	Ref			0
	N-DMT	NA				0
Time until DMT restart postpartum	H-DMT	>8 weeks	3.3	1.7–7.4	<0.001	2
		4–8 weeks	2.1	1.4–4.4	<0.001	1
		<4 weeks	Ref			0
	M-DMT	>12 weeks	2.2	1.5–4.8	<0.001	1
		≤ 12 weeks	Ref			0
	N-DMT	>12 weeks	1.9	1.2–3.4	0.011	1
		≤ 12 weeks	Ref			0

DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; H-DMT, highly effective DMT comprising natalizumab and fingolimod; M-DMT, moderately effective DMT including interferon-beta preparations, glatiramer acetate, dimethyl fumarate, or teriflunomide; N-DMT, no DMT; HR, hazard ratio; Ref., reference category. Calculated by the multivariate Cox regression model (pseudo R-squared: 0.733; omnibus p < 0.001).